Mitotane has a strong and a durable inducing effect on CYP3A4 activity

European Journal of Endocrinology

Volumn 164, Issue 4, 2011, Pages 621-626

  Van Erp, Nielka P ^a   Guchelaar, Henk Jan ^a   Ploeger, Bart A ^b   Romijn, Johannes A ^a   Den Hartigh, Jan ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; MIDAZOLAM; MITOTANE; SUNITINIB;

ADRENAL CORTEX ADENOMA; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; MALE; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; ADRENAL CORTEX CARCINOMA; AGED; CANCER COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EXPOSURE; MOLECULAR PROBE; PHENOTYPIC VARIATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; ENZYME ACTIVATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MITOTANE; PYRROLES;

EID: 79953193793     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0956     Document Type: Article

References (27)

1. Bergenstal DM, Lipsett MB, Moy RH & Hertz R. Regression of adrenal cancer and suppression of adrenal function in man by o,p' DDD. Transactions of the Association of American Physicians 1959 72 341-350.
2. Allolio B, Hahner S, Weismann D & Fassnacht M. Management of adrenocortical carcinoma. Clinical Endocrinology 2004 60 273-287. (doi:10.1046/j.1365-2265.2003.01881.x)
3. Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD & Wotring LL. Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemotherapy and Pharmacology 1997 39 537-540. (doi:10.1007/s002800050610)
4. Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE & Wotring LL. Metabolic activation and binding of mitotane in adrenal cortex homogenates. Journal of Pharmaceutical Sciences 1995 84 134-138. (doi:10.1002/jps.2600840203)
5. Martz F & Straw JA. Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metabolism and Disposition 1980 8 127-130.
6. Hahner S & Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 2005 6 386-394. (Pubitemid 40561415)
7. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M. Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 1385-1392. (doi:10.1002/1097- 0142(20010915) 92:6〈1385::AID-CNCR1461〉3.0.CO;2-2)
8. Street JC. VI. Biochemical and pathological effects. Organochlorine insecticides and the stimulation of liver microsome enzymes. Annals of the New York Academy of Sciences 1969 160 274-290. (doi:10.1111/j.1749-6632.1969. tb15848.x)
9. Cuddy PG & Loftus LS. Influence of mitotane on the hypoprothrombinemic effect of warfarin. Southern Medical Journal 1986 79 387-388. (doi:10.1097/00007611-198603000-00037)
10. Hague RV, May W & Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clinical Endocrinology 1989 31 51-57. (doi:10.1111/j.1365-2265.1989.tb00453.x)
11. Haak HR, Caekebeke-Peerlinck KM, van Seters AP & Briet E. Prolonged bleeding time due tomitotane therapy. European Journal of Cancer 1991 27 638-641. (doi:10.1016/0277-5379(91)90233-4)
12. Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR & Besser GM. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Quarterly Journal of Medicine 1992 84 671-679.
13. Magnusson MO, Dahl ML, Cederberg J, Karlsson MO & Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clinical Pharmacology and Therapeutics 2008 84 52-62. (doi:10.1038/sj.clpt.6100431)
14. Fuhr U, Jetter A & Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clinical Pharmacology and Therapeutics 2007 81 270-283. (doi:10.1038/sj.clpt.6100050)
15. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R & Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clinical Cancer Research 2007 13 1367-1373. (doi:10.1158/1078-0432.CCR-06-2328)
16. van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den HM, Chen Z, den HJ, Konig-Quartel JM, Guchelaar HJ & Gelderblom H. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemotherapy and Pharmacology, 2010 In press. (doi:10.1007/s00280-010-1367-0)
17. Moolenaar AJ, Niewint JW & Oei IT. Estimation of o,p'-DDD in plasma by gas-liquid chromatography. Clinica Chimica Acta 1977 76 213-218. (doi:10.1016/0009-8981(77)90098-5)
18. Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H & Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2008 874 84-88. (doi:10.1016/j.jchromb.2008.09.007)
19. Bristol-Myers Squibb. Drug label Lysodren approved 28/04/2004. Available at: http://www.emea.europa.eu/,Accessed on August 2010.
20. Houk BE, Bello CL, Kang D & Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clinical Cancer Research 2009 15 2497-2506. (doi:10.1158/1078-0432.CCR-08-1893)
21. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P & Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology 2006 24 25-35. (doi:10.1200/JCO.2005.02.2194)
22. Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G & Drewelow B. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. European Journal of Clinical Pharmacology 2009 65 81-87. (doi:10.1007/s00228-008-0554-y)
23. Farkas D, Oleson LE, Zhao Y, Harmatz JS, Zinny MA, Court MH & Greenblatt DJ. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. Journal of Clinical Pharmacology 2007 47 286-294. (doi:10.1177/0091270006298359)
24. Kim RB,Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ & Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research 1999 16 408-414. (doi:10.1023/A:1018877803319)
25. Kurnik D,Wood AJ &Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clinical Pharmacology and Therapeutics 2006 80 228-234. (doi:10.1016/j.clpt.2006.06.002)
26. The Trustees of Indiana University. P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.asp, accessed June 2009.
27. Chung E, Nafziger AN, Kazierad DJ & Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clinical Pharmacology and Therapeutics 2006 79 350-361. (doi:10.1016/j.clpt.2005.11.016)